Controlled drug delivery system using the conjugation of drug to biodegradable polyester

• US 6,589,548 B1
• Filed: 11/14/2000
• Issued: 07/08/2003
• Est. Priority Date: 05/16/1998
• Status: Expired due to Fees

• Current Assignee: Korea Advanced Institute of Science and Technology, Mogam Biotechnology Research Institute
• Original Assignee: Korea Advanced Institute of Science and Technology, Mogam Biotechnology Research Institute
• Inventors: Nam, Yoon Sung, Park, Tae Gwan, Lee, Keon Hyoung, Oh, Jong Eun
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): TRAN, SUSAN T
• Application Number:
  US09/700,380
• Time in Patent Office: 966 Days
• Field of Search: 424/489, 424/490, 424/426, 424/451, 424/501, 424/450, 424/497
• US Class Current: 424/426
• CPC Class Codes: A61K 47/6927 the form being a solid microparticle having no hollow or gas-filled cores
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to a molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect, Moreover, a high loading efficiency of hydrophilic drugs can be achieved.

Claims

1. A method for manufacturing a sustained controlled release system wherein a drug molecule to be released is directly conjugated to a biodegradable polyester polymer via a covalent bond, comprising the steps of:

1) forming an activated polymer solution by activating a biodegradable polyester polymer by mixing with coupling agents selected from the group consisting of bis(2-oxo-3-oxazolydinyl)phosphonic chloride (BOP—

Cl), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), dicyclohexyl carbodiimide, disuccinimidyl carbonate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimde (DIPC), 2-(1H-benzotrioxazolyl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (TBTU), 2-(5-norboren)-2,3-dicarboxyimido)-1,1,3,3-tetramethyluronium tetrafluoroborate (TNTU), para-nitrophenylchloroformate, and O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU), bases, and optionally additives;

2) directly conjugating a drug molecule with said polymer by adding said drug molecule to the activated polymer solution of step 1, and

3) purifying the polymer-molecule conjugate resulting from step 2.

2. The method of claim 1, wherein the base of step 1 is selected from the group consisting of triethylamine, N-methylmorpholine, pyridine, 1,8-diazabicyclo[5,4,0]-undec-7-ene, N,N-dimethyl aminopyridine, and N,N-diisopropyl ethylamine.

3. The method of claim 1, wherein the additives of step 1 are selected from the group consisting of hydroxybenzotriazole, pentafluorophenol and N-hydroxy-5-norboren-endo-2,3-dicarboximide.

4. A method of preparing a sustained controlled release system wherein a drug molecule to be released is directly conjugated to a biodegradable polyester polymer via a covalent bond, comprising the steps of:

1) forming an activated drug molecule solution by activating a drug molecule by mixing with coupling agents selected from the group consisting of bis(2-oxo-3-oxazolydinyl)phosphonic chloride (BOP—

Cl), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), dicyclohexyl carbodiimide, disuccinimidyl carbonate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), bis(2-oxo-3-oxazolydinyl)phosphin, diisopropyl carbodiimide (DIPC), 2-(1H-benzotrioxazolyl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (TBTU), 2-(5-norboren)-2,3-dicarboxyimido)-1,1,3,3-tetramethyluronium tetrafluoroborate (TNTU), para-nitrophenylchloroformate, and O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU), bases, and optionally, additives;

2) directly conjugating the activated drug molecules resulting from step

     1) with a biodegradable polyester polymer by adding a polymer to said activated drug molecule solution of step 1 and

3) purifying the polymer-molecule conjugate resulting from step 2.